Simoons M L, Vos J, Tijssen J G, Vermeer F, Verheugt F W, Krauss X H, Cats V M
Thoraxcenter, Erasmus University Rotterdam, The Netherlands.
J Am Coll Cardiol. 1989 Dec;14(7):1609-15. doi: 10.1016/0735-1097(89)90003-x.
Patients (n = 533) who participated in the Interuniversity Cardiology Institute of the Netherlands Trial were followed up for 3 to 7 years. The 5 year survival rate after thrombolytic therapy with intracoronary streptokinase was 81% (269 patients) compared with 71% after conventional therapy (264 patients). The greatest improvement in survival was observed in patients with anterior infarction (81% versus 64% with thrombolytic therapy or conventional therapy, respectively), in those with heart failure on admission or a previous infarction and in those with extensive myocardial ischemia on admission. Left ventricular ejection fraction at the time of hospital discharge was better after thrombolytic therapy. In the hospital survivors, long-term outcome was related to left ventricular function at the time of discharge and, to a lesser extent, to the underlying coronary artery disease. The initial therapy (thrombolysis or conventional) was not an independent additional determinant of long-term survival when left ventricular function and coronary status at the time of hospital discharge were taken into account. Thus, the salutary effects of thrombolytic therapy appear to be the result of myocardial salvage. Reinfarction within 3 years was observed more frequently after thrombolytic therapy, particularly in patients with inferior wall infarction and those with greater than or equal to 90% stenosis of the infarct-related vessel at discharge. Coronary bypass surgery and coronary angioplasty were performed more frequently after thrombolytic therapy than in conventionally treated patients. At 5 years, approximately 40% of patients in both groups had an uneventful course without reinfarction or additional revascularization procedures. These observations demonstrate that the benefits of thrombolytic therapy are maintained throughout 5 years of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
参与荷兰大学间心脏病学研究所试验的533例患者接受了3至7年的随访。冠状动脉内链激酶溶栓治疗后的5年生存率为81%(269例患者),而传统治疗后的5年生存率为71%(264例患者)。在急性前壁心肌梗死患者(溶栓治疗组和传统治疗组的生存率分别为81%和64%)、入院时伴有心力衰竭或既往有心肌梗死的患者以及入院时伴有广泛心肌缺血的患者中,生存率改善最为明显。溶栓治疗后出院时的左心室射血分数更佳。在出院存活的患者中,长期预后与出院时的左心室功能有关,在较小程度上还与潜在的冠状动脉疾病有关。当考虑到出院时的左心室功能和冠状动脉状况时,初始治疗(溶栓或传统治疗)并非长期生存的独立额外决定因素。因此,溶栓治疗的有益效果似乎是心肌挽救的结果。溶栓治疗后3年内再梗死更为常见,尤其是下壁心肌梗死患者以及出院时梗死相关血管狭窄大于或等于90%的患者。与传统治疗的患者相比,溶栓治疗后冠状动脉搭桥手术和冠状动脉成形术的实施更为频繁。5年后,两组中约40%的患者病情平稳,无再梗死或额外的血运重建手术。这些观察结果表明,溶栓治疗的益处贯穿5年随访期。(摘要截取自250词)